27620 Effects of ruxolitinib cream in patients with atopic dermatitis with baseline body surface area ≥10% and Eczema Area and Severity Index score ≥16: Pooled results from two phase 3 studies

Abstract

Atopic dermatitis (AD), a highly pruritic inflammatory skin disease, is often stratified using objective (Investigator’s Global Assessment [IGA], Eczema Area and Severity Index [EASI], body surface area [BSA]) and subjective (eg, itch numerical rating scale [NRS]) assessment tools. Efficacy and safety of ruxolitinib cream, a Janus kinase (JAK) 1/JAK2 inhibitor, was investigated in two phase 3 randomized studies (TRuE-AD1 [NCT03745638]; TRuE-AD2 [NCT03745651]) that enrolled patients aged ≥12 years with AD for ≥2 years, an IGA score of 2 or 3, and 3%–20% affected BSA.